Literature DB >> 21129397

Seroprevalence of IgG antibodies against 13 vaccine Streptococcus pneumoniae serotypes in the Netherlands.

K E M Elberse1, S C de Greeff, N Wattimena, W Chew, C S Schot, J E van de Pol, J G J van der Heide, A van der Ende, F R M van der Klis, G A M Berbers, L M Schouls.   

Abstract

In this study the seroprevalence of IgG antibodies against 13 vaccine serotypes of the pneumococcus was assessed in the Netherlands. Sera from 7904 persons obtained in a cross-sectional population-based study were analysed. The 13 serotype specific IgG concentrations were assessed simultaneously using a fluorescent bead-based multiplex immuno assay (MIA). Overall, the geometric mean IgG concentrations (GMCs) against the 13 serotypes in unvaccinated individuals increased with age up to 5 years and remained at a plateau thereafter. The data also show that individuals develop antibodies against an increasing number of different serotypes with increasing age. The highest GMCs were found for antibodies directed against serotype 14 and 19F, whereas antibodies against serotypes 4 and 5 had the lowest GMCs. There was no uniform relationship between the occurrence of serotypes causing invasive pneumococcal disease (IPD) and the GMCs against these serotypes. Increased IPD incidence in the elderly did not seem to be the result of a decline in the concentration of IgG antibodies. Copyright Â
© 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21129397     DOI: 10.1016/j.vaccine.2010.11.054

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  5 in total

1.  Avidity of antibodies against infecting pneumococcal serotypes increases with age and severity of disease.

Authors:  Amelieke J H Cremers; Jonneke Lut; Peter W M Hermans; Jacques F Meis; Marien I de Jonge; Gerben Ferwerda
Journal:  Clin Vaccine Immunol       Date:  2014-04-23

2.  Nasal carriage of Streptococcus pneumoniae serotypes and Staphylococcus aureus in Streptococcus pneumoniae-vaccinated and non-vaccinated young children.

Authors:  N H T M Dukers-Muijrers; E Stobberingh; P Beisser; R C H Boesten; P Jacobs; C J P A Hoebe
Journal:  Epidemiol Infect       Date:  2012-06-12       Impact factor: 4.434

3.  Safety and immunogenicity of a new 13-valent pneumococcal conjugate vaccine versus a licensed 7-valent pneumococcal conjugate vaccine: a study protocol of a randomised non-inferiority trial in China.

Authors:  Jing Jing Chen; Lin Yuan; Zhen Huang; Nian Min Shi; Yu Liang Zhao; Sheng Li Xia; Guo Hua Li; Rong Cheng Li; Yan Ping Li; Shu Yuan Yang; Jie Lai Xia
Journal:  BMJ Open       Date:  2016-10-19       Impact factor: 2.692

4.  A case series evaluating the serological response of adult asthma patients to the 23-valent pneumococcal polysaccharide vaccine.

Authors:  C R Laratta; K Williams; D Vethanayagam; M Ulanova; H Vliagoftis
Journal:  Allergy Asthma Clin Immunol       Date:  2017-06-07       Impact factor: 3.406

5.  Dynamics and Determinants of Pneumococcal Antibodies Specific against 13 Vaccine Serotypes in the Pre-Vaccination Era.

Authors:  Annemarijn C Prins-van Ginkel; Guy A M Berbers; Lucienne H Grundeken; Irina Tcherniaeva; Jelle I Wittenberns; Karin Elberse; Liesbeth Mollema; Hester E de Melker; Mirjam J Knol
Journal:  PLoS One       Date:  2016-01-21       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.